Filing Details

Accession Number:
0001181431-13-003232
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-01-15 16:16:27
Reporting Period:
2013-01-11
Filing Date:
2013-01-15
Accepted Time:
2013-01-15 16:16:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
819050 Vical Inc VICL Biological Products, (No Disgnostic Substances) (2836) 930948554
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1198238 B Vijay Samant 10390 Pacific Center Court
San Diego CA 92121
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock $.01 Par Value Acquisiton 2013-01-11 84,600 $0.01 654,424 No 4 P Direct
Common Stock $.01 Par Value Disposition 2013-01-11 2,634 $3.31 651,790 No 4 F Direct
Common Stock $.01 Par Value Disposition 2013-01-13 5,883 $3.31 645,907 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 F Direct
No 4 F Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Acquisiton 2013-01-11 35,250 $0.00 35,250 $3.31
Common Stock Nonstatutory Stock Option (right to buy) Acquisiton 2013-01-11 446,750 $0.00 446,750 $3.31
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,012,250 2014-01-11 2023-01-10 No 4 A Direct
2,459,000 2014-01-11 2023-01-10 No 4 A Direct
Footnotes
  1. Represents shares withheld for taxes upon the release of restricted stock granted on January 11, 2010.
  2. Represents shares withheld for taxes upon the release of restricted stock granted on January 13, 2012.
  3. This balance includes 239,850 unvested restricted stock units.
  4. Shares were acquired pursuant to a restricted stock grant.
  5. The right to exercise the above stock options generally vests 25% on the first anniversary date of the grant, with the remaining rights vesting quarterly over the remaining three years.